JPM 2016: Big Pharma Committed To Emerging Markets Despite Volatility
This article was originally published in PharmAsia News
What's in store in 2016 for big pharma in emerging markets amid increasing volatility in this sector? A number of top executives shared their views at the recent JP Morgan Healthcare Conference, and the overall message was one of continuing commitment and expansion and need for balance with the rest of the business.
You may also be interested in...
As China tightens its grip over clinical research using human genetic data in the country, and the US increases scrutiny over the use of personal data, multinational drug developers may face a difficult choice or even create separate entities to cater to local regulatory requirements. WuXi NextCODE provides one interesting case study.
Amid a sweeping National Security Law passage, many biotech and healthcare firms from China opt for a Hong Kong initial public offering in the meanwhile appetite for a US listing wanes.
The move may signal China is accelerating the vaccine to hit the general market soon, but a false impression of the vaccine’s safety may be potentially misleading, says one regulatory expert.